Perrigo (PRGO) Competitors $26.74 -0.46 (-1.69%) Closing price 07/7/2025 03:59 PM EasternExtended Trading$26.76 +0.02 (+0.07%) As of 07/7/2025 06:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock PRGO vs. CORT, JAZZ, SUPN, PCRX, NKTR, OMER, ASMB, CPIX, LLY, and JNJShould you be buying Perrigo stock or one of its competitors? The main competitors of Perrigo include Corcept Therapeutics (CORT), Jazz Pharmaceuticals (JAZZ), Supernus Pharmaceuticals (SUPN), Pacira BioSciences (PCRX), Nektar Therapeutics (NKTR), Omeros (OMER), Assembly Biosciences (ASMB), Cumberland Pharmaceuticals (CPIX), Eli Lilly and Company (LLY), and Johnson & Johnson (JNJ). These companies are all part of the "pharmaceuticals" industry. Perrigo vs. Its Competitors Corcept Therapeutics Jazz Pharmaceuticals Supernus Pharmaceuticals Pacira BioSciences Nektar Therapeutics Omeros Assembly Biosciences Cumberland Pharmaceuticals Eli Lilly and Company Johnson & Johnson Perrigo (NYSE:PRGO) and Corcept Therapeutics (NASDAQ:CORT) are both mid-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, profitability, institutional ownership, media sentiment, earnings and analyst recommendations. Does the media favor PRGO or CORT? In the previous week, Corcept Therapeutics had 12 more articles in the media than Perrigo. MarketBeat recorded 21 mentions for Corcept Therapeutics and 9 mentions for Perrigo. Corcept Therapeutics' average media sentiment score of 0.84 beat Perrigo's score of 0.66 indicating that Corcept Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Perrigo 4 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Corcept Therapeutics 12 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Is PRGO or CORT more profitable? Corcept Therapeutics has a net margin of 19.33% compared to Perrigo's net margin of -4.16%. Corcept Therapeutics' return on equity of 20.40% beat Perrigo's return on equity.Company Net Margins Return on Equity Return on Assets Perrigo-4.16% 8.93% 3.87% Corcept Therapeutics 19.33%20.40%16.64% Which has higher earnings & valuation, PRGO or CORT? Corcept Therapeutics has lower revenue, but higher earnings than Perrigo. Perrigo is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPerrigo$4.37B0.84-$171.80M-$1.31-20.41Corcept Therapeutics$675.04M10.61$141.21M$1.1658.22 Do analysts rate PRGO or CORT? Perrigo currently has a consensus target price of $33.00, indicating a potential upside of 23.41%. Corcept Therapeutics has a consensus target price of $138.25, indicating a potential upside of 104.69%. Given Corcept Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Corcept Therapeutics is more favorable than Perrigo.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Perrigo 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.25Corcept Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals and insiders believe in PRGO or CORT? 95.9% of Perrigo shares are owned by institutional investors. Comparatively, 93.6% of Corcept Therapeutics shares are owned by institutional investors. 0.4% of Perrigo shares are owned by company insiders. Comparatively, 20.5% of Corcept Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has more volatility & risk, PRGO or CORT? Perrigo has a beta of 0.45, meaning that its share price is 55% less volatile than the S&P 500. Comparatively, Corcept Therapeutics has a beta of 0.15, meaning that its share price is 85% less volatile than the S&P 500. SummaryCorcept Therapeutics beats Perrigo on 13 of the 16 factors compared between the two stocks. Get Perrigo News Delivered to You Automatically Sign up to receive the latest news and ratings for PRGO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PRGO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRGO vs. The Competition Export to ExcelMetricPerrigoMED PRODUCTS IndustryMedical SectorNYSE ExchangeMarket Cap$3.74B$10.52B$5.52B$20.71BDividend Yield4.26%2.07%5.24%3.72%P/E Ratio-20.4116.9127.1927.80Price / Sales0.8428.87395.2247.12Price / Cash5.3923.9726.2118.22Price / Book0.843.637.924.59Net Income-$171.80M$235.43M$3.17B$982.91M7 Day Performance-2.32%-0.32%1.79%0.65%1 Month Performance2.14%-0.33%1.28%4.26%1 Year Performance3.97%-10.48%33.32%13.93% Perrigo Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRGOPerrigo4.834 of 5 stars$26.74-1.7%$33.00+23.4%+5.1%$3.74B$4.37B-20.418,379Analyst UpgradeCORTCorcept Therapeutics4.6916 of 5 stars$73.40+0.2%$138.25+88.4%+124.5%$7.78B$685.45M63.28300JAZZJazz Pharmaceuticals4.8967 of 5 stars$106.12-0.7%$184.00+73.4%+6.3%$6.42B$4.07B14.152,800SUPNSupernus Pharmaceuticals2.8085 of 5 stars$31.52+1.2%$36.00+14.2%+20.8%$1.76B$661.82M28.40580PCRXPacira BioSciences3.4122 of 5 stars$23.90+1.8%$26.44+10.6%+10.3%$1.11B$702.77M-10.48720Positive NewsNKTRNektar Therapeutics4.562 of 5 stars$25.84+0.3%$84.17+225.7%+21.3%$320.67M$98.43M-2.69220Gap UpHigh Trading VolumeOMEROmeros3.5492 of 5 stars$3.00-6.3%$18.00+500.0%-20.3%$175.77MN/A-1.13210ASMBAssembly Biosciences3.7423 of 5 stars$18.12+4.7%$33.00+82.1%+40.5%$138.44M$28.52M-2.91100High Trading VolumeCPIXCumberland Pharmaceuticals0.5503 of 5 stars$3.35+28.8%N/A+107.5%$50.12M$37.87M-13.4080LLYEli Lilly and Company4.9869 of 5 stars$779.35+0.5%$1,011.61+29.8%-15.5%$738.62B$45.04B63.4147,000Trending NewsOptions VolumeJNJJohnson & Johnson4.9545 of 5 stars$152.58+0.1%$170.88+12.0%+6.0%$367.12B$88.82B16.97138,100Positive News Related Companies and Tools Related Companies Corcept Therapeutics Competitors Jazz Pharmaceuticals Competitors Supernus Pharmaceuticals Competitors Pacira BioSciences Competitors Nektar Therapeutics Competitors Omeros Competitors Assembly Biosciences Competitors Cumberland Pharmaceuticals Competitors Eli Lilly and Company Competitors Johnson & Johnson Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:PRGO) was last updated on 7/8/2025 by MarketBeat.com Staff From Our PartnersF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredInstant Cash (in 4 clicks)Since 1973, Wall Street has quietly used a strange little pricing quirk to cash flow billions. Now, for the...Awesomely, LLC | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Perrigo Company plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Perrigo With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
